AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01932918
Drug: Patient controlled analgesia
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
Trial: NCT02128321
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04648800
Drug: BCG-10 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain.
Trial: NCT04648800
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT01134432
Drug: prednisolone + mabthera
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks
Trial: NCT01134432
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
Trial: NCT02658799
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
Trial: NCT04010552
Drug: NALRINOX combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
Trial: NCT01645787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover study involving one trial with sugar pill (placebo)
Trial: NCT03790371
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal placebo tablet prior IUD insertion
Trial: NCT00435760
Drug: Placebo LAS34273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff, 1 dat treatment
Trial: NCT02463357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03742791
Drug: TS-134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg to 80 mg oral solution
Trial: NCT03742791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo oral solution
Trial: NCT02620579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
Trial: NCT03071549
Drug: Trichloroacetic acid peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
Trial: NCT01980706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill containing no pharmacologically active substance.
Trial: NCT02125877
Drug: Defearisox film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Trial: NCT01288898
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01288898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02693860
Drug: huJ591
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
Trial: NCT00786136
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin
Trial: NCT03892330
Drug: Oxytetracycline/ Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Trial: NCT03892330
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Trial: NCT03892330
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
Trial: NCT01522612
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
Trial: NCT00489827
Drug: Intravenous infusion of saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
Trial: NCT04539652
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group are treated with TenofoBell®
Trial: NCT00930163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT00364000
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate in 240 chronic HD patients
Trial: NCT01827865
Drug: Etodolac Extended Release Tablets USP 600mg
RxNorm normalized name: etodolac Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac Extended Release Tablets USP 600mg once a day
Trial: NCT01827865
Drug: Etodolac Extended Release Tablets 600mg
RxNorm normalized name: etodolac Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac Extended Release Tablets 600mg once a day
Trial: NCT02448368
Drug: RDEA3170, 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
Trial: NCT02448368
Drug: RDEA3170, 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Trial: NCT01958073
Drug: Conjugated Estrogen Vaginal Cream
RxNorm normalized name: estrogens, conjugated (USP) Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01958073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03245827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule 25mg twice a week
Trial: NCT00898287
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
Trial: NCT01959295
Drug: ASP2151 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT01953536
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
Trial: NCT02297399
Drug: PEG-ascorbate 2L
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken.
Trial: NCT00213252
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six daily doses of oral prednisolone
Trial: NCT00103805
Drug: levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02537314
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
Trial: NCT02512068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT01005537
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00003392
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 gm/m2 IV, day 1
Trial: NCT03168256
Drug: CF101 3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 tablets, 3mg BID for 16 weeks
Trial: NCT03168256
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, BID for 16 weeks
Trial: NCT00564954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day for 7 days
Trial: NCT01514188
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
Trial: NCT02493426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750581
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
Trial: NCT01755494
Drug: Mertformin XR 2 x 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR oral tablet 2 x 500 mg, single dose
Trial: NCT01755494
Drug: Komboglyze XR 5/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
Trial: NCT01755494
Drug: Komboglyze XR 5/1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
Trial: NCT01860625
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01392963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29-40 U 0.9% NaCl injection
Trial: NCT01689779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator drug
Trial: NCT02026687
Drug: Epidural
RxNorm normalized name: Epidural 17g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02145091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral placebo (lactose pill).
Trial: NCT03536741
Drug: General Intravenous Anesthetic
RxNorm normalized name: General intravenous anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Intravenous Anesthetic
Trial: NCT02755649
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01049178
Drug: Oral Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
Trial: NCT01049178
Drug: Oral Silymarin, maintenance dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
Trial: NCT01049178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03428711
Drug: Mesoglycan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months.
Trial: NCT03428711
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indistinguible placebo tablet
Trial: NCT03420911
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03251170
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
Trial: NCT01499368
Drug: Lafutidine
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 20mg/day
Trial: NCT01068262
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo tablet administered once weekly for 4 consecutive weeks
Trial: NCT00576108
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: NCT04414618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
Trial: NCT02590965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
Trial: NCT04221230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00181558
Drug: Zoledronic Acid (Zometa)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00641225
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
Trial: NCT01399658
Drug: 3'-Deoxy-3'-18f-Fluorothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessing tumor proliferation in Gynecologic cancer
Trial: NCT02279108
Drug: isotope
RxNorm normalized name: Radioisotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection, 20 MBq techntium99, intradermal use
Trial: NCT04230902
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular knee injection of corticosteroid
Trial: NCT01474200
Drug: IV Loop Diuretics (LD)
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial.
Trial: NCT01625988
Drug: LY2951742
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01625988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00294580
Drug: Maloprim
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00824343
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
Trial: NCT01495702
Drug: NNRTI
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
Trial: NCT01493921
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Trial: NCT01375179
Drug: KRP203
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01375179
Drug: Placebo matching KRP203
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00599053
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg IV per dose given for 10 days
Trial: NCT04612062
Drug: CEE321
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE321 administered to all subjects
Trial: NCT01207895
Drug: [18F]-fluorodeoxythymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
Trial: NCT02370524
Drug: [18F]T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
Trial: NCT02661217
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
Trial: NCT03168334
Drug: IDP-123 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.045% Lotion
Trial: NCT01644617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rapidly dissolving tablets administered sublingually once daily
Trial: NCT01644617
Drug: MK-8237 6 DU
RxNorm normalized name: vitamin MK 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily